Navigation Links
Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
Date:2/22/2008

NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced that the Company will focus on its new drug discovery programs targeting Hepatitis C, and drug-resistant bacterial and fungal infections, and will discontinue all development programs for pafuramidine maleate ("pafuramidine"), an investigational therapy. The decision was made in response to recent reports related to additional events identified in a cohort of volunteers in a safety study involving the drug.

The cause of the liver and kidney abnormalities in the volunteers is still speculative and additional time and resources will be used to further examine these abnormalities. However, Immtech believes that the potential risk associated with further treatment of African sleeping sickness patients outweighs the benefits of further development because these patients are generally located in places where medical care may not be readily available. Additionally, the potential benefit and resources required relative to potential risk to pneumocystis pneumonia (PCP) patients does not support further development for this target market. Therefore, the Company will direct its resources to concentrate on other drug programs. Immtech's licensing partners, PAR Pharmaceutical Companies, Inc. and BioAlliance Pharma SA, remain in full support of the Company.

Immtech was informed in late December 2007 that a sub-group of volunteers in the safety study who were treated with pafuramidine experienced liver abnormalities. In response to that finding, Immtech announced that all clinical trials involving pafuramidine would be placed on clinical hold pending completion of a comprehensive analysis of these abnormalities. All volunteers now have norm
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Immtech Announces Posting of Annual Shareholders Meeting Presentation
2. Immtech Reports Fiscal Second Quarter 2008 Results
3. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Chinese SFDA Grants Immtech Fast Track Status
7. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
8. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
9. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... 2015 Flexpoint Ford, a private equity firm ... announced that it has entered into a partnership with ... to form Kastle Therapeutics, LLC (Kastle).  The new company, ... on acquiring, developing and commercializing pharmaceuticals targeted toward diseases ... select therapies already approved for marketing, as well as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... 22, 2011 United Seating & Mobility (USM) ... transaction with Central Kentucky Mobility (CKM) to acquire and merge ... for Lexington, Louisville, as well as central, eastern and southern ... team strengthens our position within a core market for us ...
... WOONSOCKET, R.I., July 22, 2011 CVS Caremark Corporation ... conference call on Thursday, August 4, 2011, at 8:30 ... second quarter 2011 financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... will be broadcast simultaneously through the Investor Relations portion ...
Cached Medicine Technology:CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... The Clinical Data Interchange ... pleased to announce that data standards for clinical research in the areas of ... CDISC website . These three Therapeutic Area (TA) standards were developed per the ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing berry-flavored ... a simple way to get the natural ingredients that may help with body ...
(Date:7/30/2015)... ... ... Google recently announced that it will be disclosing any incidents involving its ... 8, 2015 article published by Nasdaq , the powerful tech company maintains that ... cars, which such industry players as Tesla CEO Elon Musk believe may very well ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Center,” to announce its position as one of Medicare’s top-rated care centers. ... members support the CMS rating system, which monitors health inspections, staffing, and ...
(Date:7/30/2015)... ... 2015 , ... Zejax is a New Way of Training ... , World renown body weight trainer, Paul Ziachik, announces today that he ... a person’s training capability. , The American College of Sports Medicine states that ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
... is a common problem in patients with chronic rhinosinusitis ... function, and quality of life (QOL), according to new ... Otolaryngology Head and Neck Surgery . ... and may have the following symptoms for 12 weeks ...
... 1, 2011) Endoscopic removal of pre-cancerous cells ... recommended rather than surveillance, according to a new ... Esophagus," published by the American Gastroenterological Association (AGA) ... Gastroenterology , the official journal of the ...
... Lymph node dissection, the current standard surgical treatment for ... screen-detected early stage cases , according to a study published ... Oncology (JTO), the official journal of the International Association ... nodal involvement is very low in early-stage cancers with a ...
... and Opportunistic Infections is taking place at the Hynes ... 2. Day two of this major HIV/AIDS research conference ... the National Institute of Allergy and Infectious Diseases (NIAID), ... HIV/TB Co-Infection , Diane Havlir, M.D., of the ...
... hundred years ago are being used in the development of ... time old bones have been used in this way. ... latest computer modelling techniques developed at the University of Leeds, ... With Engineering and Physical Sciences Research Council (EPSRC) funding, ...
Cached Medicine News:Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2Health News:Effects of depression on quality of life improvement after endoscopic sinus surgery 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 3Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 3Health News:CROI -- Day 2: Selected highlights of NIH-supported research 4Health News:Learning from old bones to treat modern back pain 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: